MedTrace Logo

Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients

NCT02251353 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2020-02-21

No results posted yet for this study

Summary

The number of intervention performed for metastatic breast cancer has dramatically increased over the past 2 decades. Hepatectomy and pulmonary resection for stage IV colorectal cancer is now considered the standard of care for resectable patients with isolated hepatic and/or pulmonary disease and acceptable performance status. However, the indications for resection / intervention of breast cancer origin metastases are not as clearly defined. The aim of this study to focus on emerging data for the intervention (resection and/or radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic radiosurgery) of breast cancer metastatic disease to the lung and liver, with a focus on indications for resection / intervention.

Conditions

Interventions

PROCEDURE

intervention

hepatic and/or pulmonary resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization, CyberKnife stereotactic radiosurgery

DRUG

systemic treatment

Systemic therapy

Sponsors & Collaborators

  • Federation of Breast Diseases Societies

    lead OTHER

Principal Investigators

  • Lutfi Dogan, MD · Ankara Oncology Research and Training Hospital

  • Beyza Ozcinar, MD · Istanbul University

  • Hasan Karanlik, MD · Istanbul University Institute of Oncology Capa Istanbul

  • Atilla Soran · University of Pittsburgh

  • Serdar Ozbas, MD · Ankara Guven Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2020-06-30
Completion
2022-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02251353 on ClinicalTrials.gov